Louisiana proposes tapping a century-old patent law to cut hepatitis C drug prices
From the article:
Rachel Sachs, an associate professor of law at Washington University in St. Louis who attended the recent Johns Hopkins meeting, said she believes “the case is strong” in invoking Section 1498, even though pharmaceutical companies may have multiple patents and exclusivity periods to protect their drugs.
“The federal government has a direct financial interest in controlling hepatitis C,” Sachs said, noting that many of those infected are covered by public programs such as Medicaid or through state prison systems.
Read more here!
This article also appeared in the Washington Post.bioethics fda health care reform health law policy medicaremedicaid pharmaceuticals rachel sachs regulation